Medications for Myelofibrosis

4 results

  • inrebic

    (Fedratinib Hydrochloride)
    Celgene Corporation
    INREBIC® is indicated for treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), including cases post-polycythemia vera or post-essential thrombocythemia.

  • jakafi

    (ruxolitinib)
    Incyte Corporation
    Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.

  • ojjaara

    (Momelotinib)
    GlaxoSmithKline LLC
    OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF) in adults with anemia, including primary MF and secondary MF related to post-polycythemia vera and post-essential thrombocythemia.

  • vonjo

    (Pacritinib)
    CTI BioPharma Corp.
    VONJO is indicated for treating adults with intermediate or high-risk primary or secondary myelofibrosis (MF) and a platelet count below 50 × 10⁹/L. This approval is based on accelerated approval due to spleen volume reduction, pending confirmation of clinical benefit in further trials.